⌘K
t
On 11 June 2025, Solvonis Therapeutics plc announced the initiation of an artificial intelligence (AI) supported drug discovery programme. This programme will focus on the company's proprietary central nervous system (CNS) compound library, previously acquired through the acquisition of Awakn Life Sciences Corp. Under the scientific leadership of Professor David Nutt, Solvonis' Chief Scientific Officer, the programme will initially prioritise indications in depression and stimulant use disorders.
| Date | 11 Jun 2025 |
| Time | 07:30:00 |
| Category | Corporate updates |
| ID | 3646M |
("Solvonis" or the "Company")
Initiation of artificial intelligence supported CNS drug discovery programme
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, is pleased to announce the initiation of an artificial intelligence ("AI") supported drug discovery programme focused on its proprietary central nervous system ("CNS") compound library.
The library, acquired through the Company's recent acquisition of Awakn Life Sciences Corp. ("Awakn"), includes multiple patent-pending chemical series developed through a completed hit-to-lead programme. This body of work incorporated in silico design, in vitro screening and in vivo characterisation. The resulting dataset forms a structurally differentiated early-stage portfolio with therapeutic potential across a range of neuropsychiatric indications.
The new programme will apply AI and computational modelling techniques to enable data-driven asset prioritisation, structure-activity relationship ("SAR") analysis and translational hypothesis generation. The objective is to accelerate the identification and optimisation of high-value development candidates within the library.
Under the scientific leadership of Professor David Nutt, Solvonis' Chief Scientific Officer, the AI enabled programme will initially prioritise indications in depression and stimulant use disorders.
This initiative is distinct from Solvonis' existing preclinical programme, SVN-SDN-014, which targets post-traumatic stress disorder ("PTSD"). Together, these efforts comprise a strategically diversified R&D pipeline spanning late-stage clinical assets in Alcohol Use Disorder, a novel preclinical PTSD programme and a discovery platform focused on comorbid, high-burden neuropsychiatric conditions.
Professor David Nutt, Chief Scientific Officer of Solvonis, commented: "The integration of AI supported analytics into our discovery workflow enhances our ability to identify high-potential compounds for further development. The underlying chemistry is robust and scientifically validated, and we believe this approach will bring forward differentiated candidates in areas of persistent clinical need."
Anthony Tennyson, Chief Executive Officer of Solvonis, added: "Following the acquisition of Awakn, we now possess a CNS compound library with strong early validation. This initiative reflects our strategy to combine capital-efficient innovation with rigorous translational science as we develop next-generation therapeutics for depression, addiction, and other high-burden mental health conditions."
Enquiries:
Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
anthony@solvonis.com
Allenby Capital Limited (Financial Adviser and Joint Broker)
Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)
Guy McDougall (Sales & Corporate Broking)
+44 (0) 20 3328 5656
Singer Capital Markets (Joint Broker)
Phil Davies
+44 (0) 20 7496 3000
About Solvonis Therapeutics plc
Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange (transition category), Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.
The Company's lead programs address Alcohol Use Disorder ("AUD") and Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD program leveraging novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.
In addition, Solvonis is advancing an AI supported discovery platform built on a proprietary CNS compound library, with initial focus on depression and stimulant use disorders. This initiative expands the Company's R&D pipeline into earlier-stage innovation while maintaining strategic focus on comorbid and underserved neuropsychiatric conditions.
With a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to generate value through innovation in neuropsychiatry.